R-CVP PROTOKOLÜ

Kaynaklar:

1-Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, Offner FC, Gomez-Codina J, Belch A, Cunningham D, Wassner-Fritsch E, Stein G. Phase III Study of R-CVP Compared With Cyclophosphamide, vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma. J Clin Oncol. 2008 Jul 28.

 2. NICE. TA243 Rituximab for the first-line treatment of stage III-IV follicular lymphoma. Published Jan 2012

3- van Oers, M.H.J., R. Klasa, R.E. Marcus, et al. 2006. "Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial." Blood 108(10):3295-3301.

4- Marcus, R., K. Imrie, P. Solal-Celigny, et al. 2008. "Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma." J Clin Oncol 26(28):4579-4586. 

5- Marcus, R., K. Imrie, A. Belch, et al. 2005. "CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma." Blood. 105(4):1417-1423.

6- Portlock, C. S. and S. A. Rosenberg. 1976. "Combination chemotherapy with cyclophosphamide, vincristine, and prednisone in advanced non-Hodgkin's lymphomas." Cancer. 37(3):1275-1282.

7- Luminari, S., A. Ferrari, M. Manni, et al. 2018. “Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma.” J Clin Oncol 36(7):689-696.